

Figure 1. Response of hematologic parameters to darbepoetin. Blood and urine samples of the patient were obtained with informed consent. The ethics committee of the Palacky University Hospital approved the study. Darbepoetin was administered as a subcutaneous injection beginning at a dose of 100 µg (1.67 µg/kg) every week and continued for 3 months. There was a 3-month break in therapy, and darbepoetin was reinstated at a dose of 200 µg weekly, where it remained throughout the course of the study. Heparin assay was performed as previously described⁵ and urine hepcidin concentration was expressed as nanograms hepcidin per milligrams creatinine. Normal ranges for hematologic parameters are as follows: serum iron level, 14.5-26 µM/L; total iron-binding capacity (TIBC), 44.8-71.6 µM/L; ferritin level, 20-150 µg/L (20-150 ng/mL); hemoglobin level, 120-155 g/L (12-15.5 g/dL); and urine hepcidin level, 10-200 ng/mg creatinine.

Patients with anemia due to *DMT1* mutations are critically dependent on iron delivery to developing erythrocytes; increased transferrin saturation may be essential to deliver iron when *DMT1* activity is diminished. Thus, even if medications that increase hepcidin levels become available for treatment of iron overload, they may not benefit *DMT1* patients because increased plasma hepcidin level would limit release of iron into the bloodstream, decreasing serum iron level and transferrin

saturation, further limiting available iron for hemoglobin synthesis. Removing excess iron is probably the only viable treatment for iron overload in these patients.

Dagmar Pospisilova, Martha P. Mims, Elizabeta Nemeth, Tomas Ganz, and Josef T. Prchal

Correspondence: Martha P. Mims, One Baylor Plaza, Room 802E, Houston, TX 77035; e-mail: mmims@bcm.tmc.edu.

Supported by National Institutes of Health (NIH) grants R21 DK069851-01 (M.P.M.), R01 DK065029 (T.G.), and R01 HL50077-11 (J.T.P.); Czech Ministry of Education Grants MSM 6198959205 (D.P.) and MSM 0021620806 (J.T.P.); Czech Republic Ministry of Health grant NR/7799 (D.P.); and the Will Rogers Fund (T.G.).

References

- Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of *DMT1* in a patient with microcytic anemia and iron overload. *Blood*. 2005;105:1337-1342.
- Gunshin H, Jin J, Fujiwara Y, Andrews NC. Analysis of the E399D mutation in *SLC11A2*. *Blood*. 2005;106:2221-2222.
- Priwitzerova M, Nie G, Sheftel AD, Pospisilova D, Divoky V, Ponka P. Functional consequences of the human *DMT1* (*SLC11A2*) mutation on protein expression and iron uptake. *Blood*. 2005;106:3985-3987.
- Priwitzerova M, Pospisilova D, Prchal JT, et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. *Blood*. 2004;103:3991-3992.
- Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Heparin, a putative mediator of anemia of inflammation, is a type II acute phase protein. *Blood*. 2003;101:2461-2463.
- Iolascon A, d'Apolito M, Servadio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in *DMT1*. *Blood*. 2006;107:349-354.
- Beaumont C, Delaunay J, Hetet G, De Montalembert M, Grandchamp B, Tchernia GJ. Two new human *DMT1* mutations in a compound heterozygous patient with microcytic anemia and low iron stores. *Blood*. Prepublished on January 26, 2006, as DOI 10.1182/blood-2005-10-4269.
- Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferrremia and is concentrated in ferroportin-containing organs. *Blood*. 2005;106:2196-2199.
- Nicolas G, Chauvet C, Viatte, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest*. 2002;110:1037-1044.
- Papanikolaou G, Tzilianos M, Christakis JL, et al. Heparin in iron overload disorders. *Blood*. 2005;105:4103-4104.

To the editor:

More on prognostic significance of *FLT3/ITD* size in acute myeloid leukemia (AML)

We read with great interest the paper by Stirewalt et al¹ analyzing the prognostic significance of different *Fms*-like tyrosine kinase (*FLT3*) gene internal tandem duplication (*ITD*) size in acute myeloid leukemia (AML). There is a considerable variability in *ITD* size, and Stirewalt et al¹ suggest that with increasing size of *ITD* there is a more significant loss of autoinhibitory function of *FLT3*, translating into inferior prognosis. We would like to comment on this issue based on our results, which may suggest different conclusions.

We have analyzed 86 consecutive patients with AML, 37 men and 49 women, with a median age of 57 years (range, 18-85 years), by reverse transcriptase-polymerase chain reaction (RT-PCR) for *FLT3/ITD* mutation.² We have found 18 (20.9%) patients with *FLT3/ITD* mutations, with the highest frequency (3/8; 37.5%) in acute promyelocytic leukemia (APL). *ITD* was associated with higher white blood cell (WBC) count (67 vs 26 × 10⁹/L, *P* = .013)

and somewhat inferior survival (hazard ratio [HR] = 1.98; confidence interval [CI] 1.11-6.11; *P* = .02, when we exclude patients with APL). There was no significant difference in age, sex, cytogenetic risk, and other hematologic parameters between *FLT3/ITD*-mutated and unmutated patients.

Median *ITD* size was 70 bp (range, 30-100 bp). *ITD* size was negatively correlated with age (*R* = -0.51; *P* < .05) and cytogenetic risk (*R* = -0.58; *P* < .05) and was not correlated with WBC count, sex, or other hematologic parameters. We have divided our patients' *FLT3/ITD* mutations into long (≥ 70 bp; 11/18, 61.1%) and short *ITD* (< 70 bp; 7/18, 38.9%) subgroups. We found better survival in the long-*ITD* subgroup (HR 4.07, CI 2.28-56.32; *P* = .002)³ (Figure 1), even without patients with APL (HR 3.18, CI 1.31-27.28; *P* = .02). In the multivariate Cox proportional hazard model, with *ITD* size as continuous variable, in overall series higher age, WBC count, and poor cytogenetic risk were




Figure 1. Overall survival by FLT3/ITD size for 86 patients with AML. Kaplan-Meier estimates are shown. Marks represent censored cases. Values in parentheses are results with patients with APL excluded.

associated with poor prognosis. However, in FLT3/ITD-mutated patients, only age and WBC count were associated with prognosis, but when we excluded patients with APL, ITD size also had independent prognostic significance ($P = .05$).

In our series of patients with AML, association with prognosis was opposite to that of Stirewalt et al.¹ It is unlikely that different ITD amplification methods using cDNA² versus DNA templates¹ or different cutoff values (40 vs 70 bp) are critical. When we used the same cutoff (40 bp), in the short-ITD subgroup there were only 5 patients but the survival was still significantly shorter ($P = .02$). In our group, ITD size was negatively associated with age and cytogenetic risk—which is not observed by Stirewalt et al,¹ although values for major parameters were quite similar. Also in

Response:

Does FLT3/ITD size matter?

In this issue of *Blood*, Kusec et al describe their results examining the potential prognostic significance of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) size in 86 patients with acute myeloid leukemia (AML). Contrary to our recent publication,¹ these investigators found that patients with AML with smaller FLT3/ITDs had a worse prognosis. The exact reason for the disparity of the results between the 2 studies is uncertain. These investigators used a different screening technique, which may not be as sensitive as the method in our analyses (polymerase chain reaction/single-strand conformation polymorphism [PCR/SSCP]).² Using a less sensitive screening method will reduce the detection of the smallest ITDs, and if only the smallest ITDs are associated with favorable outcomes, the potential benefits of these small ITDs would be lost in their analyses. In addition, it was not clear from the analyses what type of therapy these patients received or if all patients received the same treatment. Differences in therapy between the 2 studies or within their study could have significant impact on their results and be responsible for some of the differences. For example, if patients receiving aggressive therapies

our group with FLT3/ITD mutation there were 3 patients with APL, all with long ITDs, but the difference was still significant when we excluded patients with APL.

Quantitatively equal activating potential of both FLT3 mutation classes (ITD and tyrosine kinase domain) and activation of additional signaling pathways, including STAT5 pathway, by FLT3/ITD may suggest qualitative differences as the basis for different biologic effects of FLT3 mutations.⁴ Thus the observed different biologic effects of different FLT3/ITDs may relate to a different activation of these additional signaling pathways. FLT3 modeling and functional studies including signaling as well as further clinical studies are warranted to resolve these puzzling and conflicting results.

Rajko Kusec, Ozren Jaksic, Slobodanka Ostojic, Ika Kardum-Skelin, Radovan Vrhovac, and Branimir Jaksic

Correspondence: Rajko Kusec, Department of Molecular Diagnostics and Department of Hematology, Dubrava University Hospital, Av G.Suska 6, 10000 Zagreb, Croatia; e-mail: rkusec@irb.hr.

References

1. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood*. 2006;107:3724-3726.
2. Kusec R, Marusic Vrsalovic M, Vranic-Bobetic T, et al. FLT3 gene ITD mutation in acute myeloid leukemia. *Zdrav Vestn*. 2004;73:1-5.
3. Kusec R, Marusic Vrsalovic M, Ostojic S, et al. *Fms*-like tyrosine kinase (FLT3) gene ITD mutation in acute myeloid leukemia [abstract]. Abstract Book of 7th Seminar New Trends in the Treatment of Acute Leukemia, Dubrovnik 11-14 September 2004: 144.
4. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. *Blood*. 2005;106:265-273.

such as transplantation were included in the analyses, these therapies must be examined as potential confounding variables. Although the findings are interesting and potentially informative, we believe that larger studies examining more patients remain necessary in order to either confirm or disprove that patients with AML with large FLT3/ITDs have an overall worse prognosis than similar patients with small FLT3/ITDs.

Derek L. Stirewalt

Correspondence: Derek L. Stirewalt, Fred Hutchinson Cancer Research Center, D5-380, 1100 Fairview Ave North, Seattle, WA 98109; e-mail: dstirewa@fhcrc.org.

References

1. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood*. 2006;107:3724-3726.
2. Stirewalt DL, Meshinchi S, Kussick SJ, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. *Br J Haematol*. 2004; 124:481-484.